Production of recombinant protein therapeutics in cultivated mammalian cells
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Cultivated mammalian cells have become the dominant system for the production of recombinant proteins for clinical applications because of their capacity for proper protein folding, assembly and post-translational modification. Thus, the quality and efficacy of a protein can be superior when expressed in mammalian cells versus other hosts such as bacteria, plants and yeast. Recently, the productivity of mammalian cells cultivated in bioreactors has reached the gram per liter range in a number of cases, a more than 100-fold yield improvement over titers seen for similar processes in the mid-1980s. This increase in volumetric productivity has resulted mainly from improvements in media composition and process control. Opportunities still exist for improving mammalian cell systems through further advancements in production systems as well as through vector and host cell engineering.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advances in cell engineering, process control, and media composition are credited with improving the volumetric yield of cell culture bioprocesses, making biopharmaceutical manufacturing more cost-effective and practical [8].”
From The role of Raman spectroscopy in biopharmaceuticals from development to manufacturing (2022) · cites this paper as [8]
In the citing paper
“Chinese hamster ovary (CHO) cells are one of the main cell lines used in the production of recombinant therapeutics (Wurm, 2004; see Grillberger et al., 2009 for examples of proteins produced in CHO cells).”
From Virus susceptibility of Chinese hamster ovary (CHO) cells and detection of viral contaminations by adventitious agent testing (2010) · cites this paper as Wurm, 2004
Citations
Cites
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451 · cited 1×
“In 1973, Graham and van der Eb showed that exposing cells to nanoparticles of DNA and calcium phosphate makes possible DNA transfer into cultivated mammalian cell”
BackgroundEpigenetic Codes for Heterochromatin Formation and Silencing
Richards, E. J., & Elgin, S. C. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00644-x · Cited by 871
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
How introns influence and enhance eukaryotic gene expression
Le Hir, H., Nott, A., & Moore, M. J. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00052-5 · Cited by 734
Bebbington, C. R., Renner, G., Thomson, S., King, D., Abrams, D., & Yarranton, G. T. (1992) · Nature Biotechnology · doi:10.1038/nbt0292-169 · Cited by 462 · cited 1×
“At a concentration of 10–100 μM MSX, resistant clones can be identified in selected NS0 cell populations that have amplified the transgene complex containing the GS gene and the desired gene(s) of interes”
BackgroundGenetic and physical linkage of exogenous sequences in transformed cells
Perucho, M., Hanahan, D., & Wigler, M. (1980) · Cell · doi:10.1016/0092-8674(80)90178-6 · Cited by 455 · cited 1×
“Nuclear ligases assure the covalent joining of individual plasmid DNA molecule”
BackgroundExpression of recombinant plasmids in mammalian cells Is enhanced by sodium butyrate
Gorman, C. M., Howard, B. H., & Reeves, R. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.21.7631 · Cited by 367 · cited 1×
“Another way to inhibit silencing is to block deacetylation of histones using butyrat”
BackgroundSilencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9
Mutskov, V., & Felsenfeld, G. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600013 · Cited by 296
Kim, S. J., Kim, N. S., Ryu, C. J., Hong, H. J., & Lee, G. M. (1998) · Biotechnology and Bioengineering · doi:10.1002/(sici)1097-0290(19980405)58:1<73::aid-bit8>3.0.co;2-r · Cited by 220 · cited 1×
“Thus, it might be advantageous to omit selective drugs once promising clonal cell lines have been identifie”
BackgroundLarge-scale transient expression in mammalian cells for recombinant protein production
Wurm, F., & Bernard, A. (1999) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)80027-5 · Cited by 203
Self-citation
Research works printed but not linked: 1
- Gorman, C.M., Howard, B.H. & Reeves, R. Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res. 11, 7631–7648 (1983). · DOI · Paper page
Cited by
Items 101–200 of 1,007
Kumar, N., Gammell, P., & CLYNES, M. M. (2007) · Cytotechnology · doi:10.1007/s10616-007-9047-6 · Cited by 183
“Today however, cells can achieve >10 · 10(6) cells/ml with specific productivities of ~90 pg/cells/day and product titres in excess of 5 g/l (Wurm 2004).”
BackgroundBackliwal, G., Hildinger, M., Hasija, V., & Wurm, F. M. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21596 · Cited by 151
Self-citationGenetic characterization of CHO production host DG44 and derivative recombinant cell lines
Derouazi, M., Martinet, D., Besuchet Schmutz, N., Flaction, R., Wicht, M., Bertschinger, M., Hacker, D. L., Beckmann, J. S., & Wurm, F. M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.111 · Cited by 152
Self-citationA Comprehensive Review on Intracellular Delivery
Rad, D. M., Rad, M. A., Bazaz, S. R., Kashaninejad, N., Jin, D., & Warkiani, M. E. (2021) · Advanced Materials · doi:10.1002/adma.202005363 · Cited by 173
Ho, S. C. L., Bardor, M., Feng, H., Mariati, Tong, Y. W., Song, Z., Yap, M. G. S., & Yang, Y. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.09.023 · Cited by 159
Chapter 11 Selecting an Appropriate Method for Expressing a Recombinant Protein
Brondyk, W. H. (2009) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(09)63011-1 · Cited by 215
Simple piggyBac transposon-based mammalian cell expression system for inducible protein production
Li, Z., Michael, I. P., Zhou, D., Nagy, A., & Rini, J. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218620110 · Cited by 153
“T desire to produce eukaryotic proteins for applications in cell biology, structural biology, and biotechnology has greatly accelerated the use of mammalian cell expression systems during the past 10 to 15 years (1, 2).”
BackgroundClincke, M., Mölleryd, C., Samani, P. K., Lindskog, E., Fäldt, E., Walsh, K., & Chotteau, V. (2013) · Biotechnology Progress · doi:10.1002/btpr.1703 · Cited by 147
“This cell density pattern was typical for a fed-batch culture as described in studies reported in previously published literature.(3,27) The viability was high ( 95%) until day 11 and the mild hypothermia at 35.”
ResultBiopharmaceuticals: recent approvals and likely directions
Walsh, G. (2005) · Trends in biotechnology · doi:10.1016/j.tibtech.2005.07.005 · Cited by 175
Al‐Fageeh, M. B., Marchant, R. J., Carden, M. J., & Smales, C. M. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20789 · Cited by 147
Improving the efficiency of CHO cell line generation using glutamine synthetase gene knockout cells
Fan, L., Kadura, I., Krebs, L. E., Hatfield, C. C., Shaw, M. M., & Frye, C. C. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24365 · Cited by 145
Shirbaghaee, Z., & Bolhassani, A. (2015) · Biopolymers · doi:10.1002/bip.22759 · Cited by 158
Metabolic analysis of antibody producing CHO cells in fed‐batch production
Dean, J., & Reddy, P. (2013) · Biotechnology and Bioengineering · doi:10.1002/bit.24826 · Cited by 137
Pezzini, J., Joucla, G., Gantier, R., Toueille, M., Lomenech, A., Sénéchal, C. L., Garbay, B., Santarelli, X., & Cabanne, C. (2011) · Journal of Chromatography A · doi:10.1016/j.chroma.2011.09.036 · Cited by 148
Grillberger, L., Kreil, T. R., Nasr, S., & Reiter, M. (2009) · Biotechnology Journal · doi:10.1002/biot.200800241 · Cited by 144
“About 60-70% of all recombinant protein therapeutics are produced in mammalian cells, primarily Chinese hamster ovary (CHO) cells [3].”
BackgroundAnti‐IgE Antibodies for the Treatment of IgE‐Mediated Allergic Diseases
Chang, T. W., Wu, P. C., Hsu, C.-L., & Hung, A. F.-H. (2007) · Advances in immunology · doi:10.1016/s0065-2776(06)93002-8 · Cited by 162
Over‐expression of secreted proteins from mammalian cell lines
Dalton, A. C., & Barton, W. A. (2014) · Protein Science · doi:10.1002/pro.2439 · Cited by 182
“ceutical production in conjunction with methotrexate induced DHFR gene amplification.(28,48) Yields of”
BackgroundDavy, A. M., Kildegaard, H. F., & Andersen, M. R. (2017) · Cell Systems · doi:10.1016/j.cels.2017.02.010 · Cited by 151
“, 2012), the heterologous gdhA promoter in Aspergillus species (Fleissner and Dersch, 2010), or viral promoters in mammalian hosts (Wurm, 2004).”
BackgroundInfluentialEukaryotic protein production in designed storage organelles
Torrent, M., Llompart, B., Lasserre-Ramassamy, S., Llop-Tous, I., Bastida, M., Marzábal, P., Westerholm‐Parvinen, A., Saloheimo, M., Heifetz, P. B., & Ludevid, M. D. (2009) · BMC Biology · doi:10.1186/1741-7007-7-5 · Cited by 138
“In general, such platforms are either highly capital-intensive mammalian cell cultures based on secreted proteins [2], or require complex and inefficient refolding of bacterially expressed proteins sequestered in insoluble inclusion bodies [3].”
BackgroundDNA methylation contributes to loss in productivity of monoclonal antibody-producing CHO cell lines
Yang, Y., Mariati, Chusainow, J., & Yap, M. G. S. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.04.004 · Cited by 158
“Production stability during long term culture is amajor concern or industries producing therapeutic proteins using mammalian ell lines (Barnes et al., 2003; Wurm, 2004).”
BackgroundEngineering mammalian cells in bioprocessing – current achievements and future perspectives
Lim, Y., Wong, N. S. C., Lee, Y. Y., Ku, S. C. Y., Wong, D. C. F., & Yap, M. G. S. (2010) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20090363 · Cited by 133
The role of Raman spectroscopy in biopharmaceuticals from development to manufacturing
Esmonde-White, K. A., Cuellar, M., & Lewis, I. R. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03727-4 · Cited by 152
“Advances in cell engineering, process control, and media composition are credited with improving the volumetric yield of cell culture bioprocesses, making biopharmaceutical manufacturing more cost-effective and practical [8].”
BackgroundOptimization of Protein Expression in Mammalian Cells
Hunter, M., Yuan, P., Vavilala, D. T., & Fox, M. (2018) · Current Protocols in Protein Science · doi:10.1002/cpps.77 · Cited by 152
“Erythropoeitin, the first recombinant protein made from mammalian cells, is still produced in adherent CHO cells cultivated in roller bottles (F. M. Wurm, 2004).”
BackgroundMethodThe Road from Host-Defense Peptides to a New Generation of Antimicrobial Drugs
Boto, A., Pérez de la Lastra, J., & González, C. (2018) · Molecules · doi:10.3390/molecules23020311 · Cited by 136
“However, the cost of producing recombinant proteins would be considerably higher than using conventional microorganisms [91].”
BackgroundSunley, K., & Butler, M. (2010) · Biotechnology Advances · doi:10.1016/j.biotechadv.2010.02.003 · Cited by 136
“Over the last twenty years improvements in cell lines, process control and media formulations have increased product titres nearly 100-fold (Wurm, 2004).”
BackgroundAn 'omics approach towards CHO cell engineering
Datta, P., Linhardt, R. J., & Sharfstein, S. T. (2013) · Biotechnology and Bioengineering · doi:10.1002/bit.24841 · Cited by 128
Decoding mechanisms by which silent codon changes influence protein biogenesis and function
Bali, V., & Bebok, Z. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.03.011 · Cited by 133
DNA delivery with hyperbranched polylysine: A comparative study with linear and dendritic polylysine
Kadlecová, Z., Rajendra, Y., Matasci, M., Baldi, L., Hacker, D. L., Wurm, F. M., & Klok, H. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.019 · Cited by 136
Self-citationGene editing for cell engineering: trends and applications
Gupta, S. K., & Shukla, P. (2017) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2016.1214557 · Cited by 127
“[81,82] This often leads to the development of heterogeneous and unwanted phenotypes, resulting in inconsistent protein production termed as “position effect variation”.[82,83] However, these clones often show reduced and inconsistent protein production over a period due to variation in”
BackgroundmRNA as novel technology for passive immunotherapy
Schlake, T., Thess, A., Thran, M., & Jordan, I. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2935-4 · Cited by 130
“Although aglycosylated IgGs can be produced in bacteria [48] , modern production processes usually take advantage of the cellular machinery for advanced posttranslational maturation and secretion of eukaryotic cells [48] [49] [50] [51] .”
BackgroundBailey, L. A., Hatton, D., Field, R., & Dickson, A. J. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24485 · Cited by 127
Daramola, O., Stevenson, J., Dean, G., Hatton, D., Pettman, G., Holmes, W., & Field, R. (2014) · Biotechnology Progress · doi:10.1002/btpr.1809 · Cited by 134
Corchero, J. L., Gasser, B., Resina, D., Smith, W., Parrilli, E., Vázquez, F., Abasolo, I., Giuliani, M., Jäntti, J., Ferrer, P., et al. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.09.001 · Cited by 133
“Main issues of this system are limited and instable productivity (Barnes et al., 2003; Butler, 2005; Wurm, 2004).”
BackgroundUltrasonic Separation of Particulate Fluids in Small and Large Scale Systems: A Review
Leong, T. S. H., Johansson, L., Juliano, P., McArthur, S. L., & Manasseh, R. (2013) · Industrial & Engineering Chemistry Research · doi:10.1021/ie402295r · Cited by 133
Antibody display technologies: selecting the cream of the crop
Valldorf, B., Hinz, S. C., Russo, G., Pekar, L., Mohr, L., Klemm, J., Doerner, A., Krah, S., Hust, M., & Zielonka, S. (2021) · Biological Chemistry · doi:10.1515/hsz-2020-0377 · Cited by 145
“The vast majority of marketed Ab therapeutics is produced in mammalian cells (Birch and Racher 2006; Wurm 2004).”
BackgroundGenomic and proteomic exploration of CHO and hybridoma cells under sodium butyrate treatment
Yee, J. C., de Leon Gatti, M., Philp, R. J., Yap, M., & Hu, W. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21665 · Cited by 130
Process control in cell culture technology using dielectric spectroscopy
Justice, C., Brix, A., Freimark, D., Kraume, M., Pfromm, P. H., Eichenmueller, B., & Czermak, P. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.03.002 · Cited by 133
“The production processes for cells or cell related products are complex, and must comply with GMP requirements [Baldi, et al., 2007, Butler, 2005, Weber et al., 2008, Weber et al., 2007a, Weber, et al., 2007b, Wurm, 2004].”
BackgroundOsterlehner, A., Simmeth, S., & Göpfert, U. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23216 · Cited by 131
Mind-controlled transgene expression by a wireless-powered optogenetic designer cell implant.
Folcher, M., Oesterle, S., Zwicky, K., Thekkottil, T., Heymoz, J., Hohmann, M., Christen, M., Daoud El-Baba, M., Buchmann, P., & Fussenegger, M. (2014) · Nature Communications · doi:10.1038/ncomms6392 · Cited by 130
Recent progress in the development of plant derived vaccines
Yusibov, V. M., & Rabindran, S. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.8.1173 · Cited by 130
Ligand–receptor interaction platforms and their applications for drug discovery
Fang, Y. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.715631 · Cited by 124
“Advances in molecular cloning and cell culture technologies have made it routine to produce many target proteins with high quality, so it is affordable to perform large-scale biochemical analysis of drug--target interactions [3].”
BackgroundCost evaluation of antibody production processes in different operation modes
Klutz, S., Holtmann, L., Lobedann, M., & Schembecker, G. (2015) · Chemical Engineering Science · doi:10.1016/j.ces.2015.10.029 · Cited by 130
Scale-Up Technologies for the Manufacture of Adherent Cells
Bellani, C. F., Ajeian, J., Duffy, L., Miotto, M., Groenewegen, L., & Connon, C. J. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.575146 · Cited by 137
“Adapting adherent cells to grow as suspension cells is often laborious as it can take months to achieve and ultimately can often be unsuccessful as not all cells are capable of fully adjusting to this new growth condition (10).”
BackgroundAntibody Conjugates with Unnatural Amino Acids
Hallam, T. J., Wold, E. D., Wahl, A. F., & Smider, V. V. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00082 · Cited by 140
Liu, B., Spearman, M. A., Doering, J., Lattová, E., Perreault, H., & Butler, M. (2013) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2013.11.007 · Cited by 142
“…antibodies (Mabs), has been et by significant increases in productivity of mammalian cell culure bioprocess over the last decade (Butler, 2005; Wurm, 2004). ed-batch culture has become the predominant strategy used for ammalian cell culture bioprocesses for biopharmaceutical prouction…”
BackgroundMauro, V. P. (2018) · BioDrugs · doi:10.1007/s40259-018-0261-x · Cited by 151
“and growth properties are identified, expression can be optimized for maximal production by adjusting culture conditions (see Wurm [26]).”
BackgroundInfluentialRecent advances in production of recombinant spider silk proteins
Chung, H., Kim, T. Y., & Lee, S. Y. (2012) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2012.03.013 · Cited by 127
Salas-Solano, O., Tomlinson, B., Du, S., Parker, M., Strahan, A., & Ma, S. (2006) · Analytical Chemistry · doi:10.1021/ac060828p · Cited by 126
Thoring, L., Dondapati, S. K., Stech, M., Wüstenhagen, D. A., & Kubick, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-12188-8 · Cited by 135
Kanda, Y., Imai, H., Kuni‐Kamochi, R., Mori, K., Inoue, M., Kitajima-Miyama, K., Okazaki, A., Iida, S., Shitara, K., & Satoh, M. (2007) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2007.04.025 · Cited by 131
Towards dynamic metabolic flux analysis in CHO cell cultures
Ahn, W. S., & Antoniewicz, M. R. (2012) · Biotechnology Journal · doi:10.1002/biot.201100052 · Cited by 119
“In addition, large bioreactors of 10 000 L or more are common these days to satisfy the growing worldwide needs for therapeutic proteins [2, 4, 5].”
BackgroundWani, S. U. D., Gautam, S. P., QADRIE, Z. L., & Gangadharappa, H. V. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.09.057 · Cited by 124
Kadlecová, Z., Baldi, L., Hacker, D. L., Wurm, F. M., & Klok, H. (2012) · Biomacromolecules · doi:10.1021/bm300930j · Cited by 123
Self-citationEmploying epigenetics to augment the expression of therapeutic proteins in mammalian cells
Kwaks, T., & Otte, A. P. (2006) · Trends in biotechnology · doi:10.1016/j.tibtech.2006.01.007 · Cited by 137
“However, during the past two decades, cultured mammalian cells have become a widely used platform for producing recombinant therapeutic proteins [ 2 ].”
BackgroundMethodInfluentialSamadi, N., Abbadessa, A., Stefano, A. D., van Nostrum, C. F., Vermonden, T., Rahimian, S., Teunissen, E. A., van Steenbergen, M. J., Amidi, M., & Hennink, W. E. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.034 · Cited by 128
“Thanks to the growing advances in biotechnology, the number of recombinant proteins available for therapeutic purposes is increasing significantly [1,2].”
BackgroundA Single-use Strategy to Enable Manufacturing of Affordable Biologics
Jacquemart, R., Vandersluis, M., Zhao, M., Sukhija, K., Sidhu, N., & Stout, J. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.06.007 · Cited by 119
“A comparison of data from typical processes from 1982 and 2004 show rises in stirredtank product titers from 50 mg/L to 4700 mg/L, with approximately 8× improvement in specific productivity [13].”
BackgroundJiang, Z., & Sharfstein, S. T. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21726 · Cited by 118
Matasci, M., Hacker, D. L., Baldi, L., & Wurm, F. M. (2008) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2008.12.003 · Cited by 139
Self-citationThe food additive vanillic acid controls transgene expression in mammalian cells and mice
Gitzinger, M., Kemmer, C., Fluri, D. A., El‐Baba, M. D., Weber, W., & Fussenegger, M. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr1251 · Cited by 128
Matasci, M., Baldi, L., Hacker, D. L., & Wurm, F. M. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23167 · Cited by 124
“Recombinant therapeutic proteins are predominantly manufactured using stable mammalian cell lines in large scale bioreactors (Wurm, 2004).”
BackgroundSelf-citationTechnological progresses in monoclonal antibody production systems
Rodrigues, M. E., Costa, A. R., Henriques, M., Azeredo, J., & Oliveira, R. (2009) · Biotechnology Progress · doi:10.1002/btpr.348 · Cited by 146
“Apart from the increased surface area for growth and low shear rates,(17,18) roller bottles have other advantages, such as very high oxygen transfer rates (supplied by the ample bottle ‘‘headspace’’(4)) and the ease of scale-up that is simply done by increasing the number of units handled in parallel.(4,19) However, t…”
BackgroundMethodInfluentialBioactives from microalgal dinoflagellates
Gallardo-Rodríguez, J. J., Sánchez‐Mirón, A., García-Camacho, F., López‐Rosales, L., Chisti, Y., & Grima, E. M. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.07.005 · Cited by 122
“This has been demonstrated in industrial cultures of animal cells, for example (Wurm, 2004).”
BackgroundHackl, M., Jakobi, T., Blom, J., Doppmeier, D., Brinkrolf, K., Szczepanowski, R., Bernhart, S. H., Siederdissen, C. H. Z., Bort, J. A. H., Wieser, M., et al. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.02.011 · Cited by 105
Knappskog, S., Ravneberg, H., Gjerdrum, C., Tröβe, C., Stern, B., & Pryme, I. F. (2006) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2006.11.026 · Cited by 114
“A lot of work concerning the optimisation of the roduction of a recombinant protein by a transfected ammalian cell line has concentrated on modulating arameters affecting cell growth such as pH, CO2, ionic trength, and cell density (Wurm, 2004).”
Identification and prevention of antibody disulfide bond reduction during cell culture manufacturing
Trexler‐Schmidt, M., Sargis, S., Chiu, J., Khoo, S., Mun, M., Kao, Y., & Laird, M. W. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22699 · Cited by 123
“After initiating a production bioreactor, various process additions and parameter manipulations are performed to maximize growth and antibody production and yield suitable product quality (Andersen and Krummen, 2002; Andersen and Reilly, 2004; Birch et al., 2005; Birch and Racher, 2006; Wurm, 2004).”
MethodGitzinger, M., Kemmer, C., El‐Baba, M. D., Weber, W., & Fussenegger, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901501106 · Cited by 121
Transient expression of human antibodies in mammalian cells
Vazquez-Lombardi, R., Névoltris, D., Luthra, A., Schofield, P., Zimmermann, C., & Christ, D. (2017) · Nature Protocols · doi:10.1038/nprot.2017.126 · Cited by 123
A simple high-yielding process for transient gene expression in CHO cells
Rajendra, Y., Kiseljak, D., Baldi, L., Hacker, D. L., & Wurm, F. M. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.03.001 · Cited by 112
Self-citationDevelopment of adjuvanted recombinant zoster vaccine and its implications for shingles prevention
Lecrenier, N., Beukelaers, P., Colindres, R. E., Curran, D., Kesel, C. D., Saegher, J.-P. D., Didierlaurent, A. M., Ledent, E., Mols, J., Mrkvan, T., et al. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1495565 · Cited by 119
“Such cell lines are commonly used for production of complex recombinant proteins requiring specific three-dimensional folding and posttranslational modifications such as asparagine-associated glycosylation patterns to retain their antigenicity [109].”
BackgroundMetabolic responses of CHO cells to limitation of key amino acids
Duarte, T. M., Carinhas, N., Barreiro, L. C., Carrondo, M. J. T., Alves, P. M., & Teixeira, A. P. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25266 · Cited by 110
Dreesen, I. A. J., & Fussenegger, M. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.22990 · Cited by 110
Brown Spider (Loxosceles genus) Venom Toxins: Tools for Biological Purposes
Chaim, O. M., Trevisan-Silva, D., Chaves‐Moreira, D., Wille, A. C. M., Ferrer, V. P., Matsubara, F. H., Mangili, O. C., da Silveira, R. B., Gremski, L. H., Gremski, W., et al. (2011) · Toxins · doi:10.3390/toxins3030309 · Cited by 125
“Mammalian cells have the capacity for proper protein folding and assembly, as well as co- and post-translational modifications [224].”
BackgroundWulhfard, S., Tissot, S., Bouchet, S., Cevey, J., de Jesus, M., Hacker, D. L., & Wurm, F. M. (2008) · Biotechnology Progress · doi:10.1021/bp070286c · Cited by 105
Self-citationRecent advances in the production of proteins in insect and mammalian cells for structural biology
Nettleship, J. E., Assenberg, R., Diprose, J. M., Rahman-Huq, N., & Owens, R. J. (2010) · Journal of Structural Biology · doi:10.1016/j.jsb.2010.02.006 · Cited by 126
“Although creation of a high producing stable cell line takes 2–6 months, after establishment of the cell line expression of protein is fast, robust and usually in high yield (Wurm, 2004).”
BackgroundA Synthetic Multifunctional Mammalian pH Sensor and CO2 Transgene-Control Device
Ausländer, D., Ausländer, S., Hamri, G. C., Sedlmayer, F., Müller, M., Frey, O., Hierlemann, A. R., Stelling, J., & Fussenegger, M. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.06.007 · Cited by 116
“Therefore, gaseous CO2 is also used to control pH in cell culture systems and biopharmaceutical manufacturing in a traceless and noninvasive manner (Wurm, 2004).”
BackgroundPybus, L. P., Dean, G., West, N. R., Smith, A. B., Daramola, O., Field, R. P., Wilkinson, S. J., & James, D. C. (2013) · Biotechnology and Bioengineering · doi:10.1002/bit.25116 · Cited by 131
Hogwood, C. E. M., Tait, A. S., Koloteva‐Levine, N., Bracewell, D. G., & Smales, C. M. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24607 · Cited by 109
“The development of mammalian cell recombinant protein bioprocesses and expression systems has resulted in reported product yields in excess of 5 g L 1 (Shukla and Thommes, 2010; Wurm, 2004).”
BackgroundStable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells
Loignon, M., Perret, S., Kelly, J., Boulais, D., Cass, B., Bisson, L., Afkhamizarreh, F., & Durocher, Y. (2008) · BMC Biotechnology · doi:10.1186/1472-6750-8-65 · Cited by 105
“In mice, the presence of contaminating partially unfolded IFN species appears to play a key role in the appearance of these antibodies [28] Human and other mammalian cells are expression systems of choice for the production of secreted recombinant proteins such as antibodies, sometimes yielding up to hundreds of milli…”
BackgroundCarinhas, N., Duarte, T. M., Barreiro, L. C., Carrondo, M. J. T., Alves, P. M., & Teixeira, A. P. (2013) · Biotechnology and Bioengineering · doi:10.1002/bit.24983 · Cited by 105
Generic Raman‐based calibration models enabling real‐time monitoring of cell culture bioreactors
Mehdizadeh, H., Lauri, D., Karry, K. M., Moshgbar, M., Procopio‐Melino, R., & Drapeau, D. (2015) · Biotechnology Progress · doi:10.1002/btpr.2079 · Cited by 108
“Mammalian cell culture processes are widely used in the pharmaceutical industry for production of a large variety of biological products.(1) These products include, but are not limited to, antibodies, therapeutic proteins, and growth factors, all serving as life-saving medicines to address an increasing number of huma…”
BackgroundSuspendable Hydrogel Nanovials for Massively Parallel Single-Cell Functional Analysis and Sorting
de Rutte, J. M., Dimatteo, R., Archang, M. M., van Zee, M., Koo, D., Lee, S., Sharrow, A. C., Krohl, P. J., Mellody, M., Zhu, S., et al. (2022) · ACS Nano · doi:10.1021/acsnano.1c11420 · Cited by 114
Generation of a triple-gene knockout mammalian cell line using engineered zinc-finger nucleases
Liu, P., Chan, E. M., Cost, G. J., Zhang, L., Wang, J., Miller, J. C., Guschin, D. Y., Reik, A., Holmes, M. C., Mott, J. E., et al. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22654 · Cited by 107
Go, E. P., Liao, H., Alam, S. M., Hua, D., Haynes, B. F., & Desaire, H. (2013) · Journal of Proteome Research · doi:10.1021/pr300870t · Cited by 107
Li, J., Menzel, C., Meier, D., Zhang, C., Dübel, S., & Jostock, T. (2006) · Journal of Immunological Methods · doi:10.1016/j.jim.2006.10.010 · Cited by 116
Cacciatore, J. J., Chasin, L. A., & Leonard, E. F. (2010) · Biotechnology Advances · doi:10.1016/j.biotechadv.2010.04.003 · Cited by 120
Mammalian Systems Biotechnology Reveals Global Cellular Adaptations in a Recombinant CHO Cell Line
Yusufi, F. N. K., Lakshmanan, M., Ho, Y. S., Loo, B. L. W., Ariyaratne, P., Yang, Y., Ng, S. K., Tan, T. R. M., Yeo, H. C., Lim, H. L., et al. (2017) · Cell Systems · doi:10.1016/j.cels.2017.04.009 · Cited by 104
“However, although overall yields frommammalian cells have increased up to 100-fold over the decades (Wurm, 2004), the corresponding per-cell yields have not been improved substantially (Carinhas et al., 2012).”
BackgroundUpstream process intensification and continuous manufacturing
Chen, C., Wong, H. E., & Goudar, C. T. (2018) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2018.10.006 · Cited by 101
Cell line‐specific control of recombinant monoclonal antibody production by CHO cells
O'Callaghan, P. M., McLeod, J., Pybus, L. P., Lovelady, C. S., Wilkinson, S. J., Racher, A. J., Porter, A., & James, D. C. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22769 · Cited by 102
Rational and systematic protein purification process development: the next generation
Nfor, B. K., Verhaert, P. D. E. M., van der Wielen, L. A. M., Hubbuch, J. J., & Ottens, M. (2009) · Trends in biotechnology · doi:10.1016/j.tibtech.2009.09.002 · Cited by 105
Assessing monoclonal antibody product quality attribute criticality through clinical studies
Goetze, A. M., Schenauer, M. R., & Flynn, G. C. (2010) · mAbs · doi:10.4161/mabs.2.5.12897 · Cited by 102
“Therapeutic monoclonal antibodies (mAbs), like other therapeutic proteins, are enormously complex drugs typically produced in mammalian tissue culture cells through recombinant DNA technology.(1,2) As a result of naturally-occurring molecular heterogeneity, imperfect cellular processing, chemical and enzymatic changes…”
BackgroundOoi, A., Wong, A., Esau, L. E., Lemtiri‐Chlieh, F., & Gehring, C. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00300 · Cited by 104
Gene amplification: mechanisms and involvement in cancer
Matsui, A., Ihara, T., Suda, H., Mikami, H., & Semba, K. (2013) · BioMolecular Concepts · doi:10.1515/bmc-2013-0026 · Cited by 116
“The amplification mechanism of the DHFR gene in MTX-resistant cells has been frequently employed for recombinant protein production in mammalian cells (12, 13).”
BackgroundOptimizing amino acid composition of CHO cell culture media for a fusion protein production
Xing, Z., Kenty, B. M., Koyrakh, I., Borys, M., Pan, S., & Li, Z. J. (2011) · Process Biochemistry · doi:10.1016/j.procbio.2011.03.014 · Cited by 103
Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay
Parekh, B. S., Berger, E., Sibley, S., Cahya, S., Liqun, X., LaCerte, M. A., Vaillancourt, P., Wooden, S. K., & Gately, D. P. (2012) · mAbs · doi:10.4161/mabs.19873 · Cited by 113
Khuat, T. T., Bassett, R., Otte, E. A., Grevis-James, A., & Gabryś, B. (2024) · Computers & Chemical Engineering · doi:10.1016/j.compchemeng.2024.108585 · Cited by 108
Buchsteiner, M., Quek, L., Gray, P. P., & Nielsen, L. K. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26724 · Cited by 107
“Mammalian cells are the preferred production host for therapeutic proteins such as monoclonal antibodies due to their ability to perform posttranslational modifications, which are essential for biological efficacy and safety (Durocher & Butler, 2009; Wurm, 2004).”
BackgroundPhysiological responses of CHO cells to repetitive hydrodynamic stress
Godoy‐Silva, R., Chalmers, J. J., Casnocha, S. A., Bass, L. A., & Ma, N. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22339 · Cited by 95
“Over the same time span, mammalian cell culture technology has also evolved rapidly (Wurm, 2004).”
BackgroundRecent Advances in Plant Biotechnology
Kirakosyan, A., & Kaufman, P. B. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0194-1 · Cited by 110
Niklas, J., Schräder, E., Sandig, V., Noll, T., & Heinzle, E. (2010) · Bioprocess and Biosystems Engineering · doi:10.1007/s00449-010-0502-y · Cited by 118
McDonald, P., Victa, C., Carter‐Franklin, J. N., & Fahrner, R. L. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.22127 · Cited by 99
“Recent increases in cell culture productivity have resulted in cell culture titers of multiple grams per liter (Wurm, 2004).”
Background
Metadata
- Authors
- Wurm, F. M.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- Corresponding author
- Wurm, Florian M
- ORCID
- Wurm, Florian M
- Venue
- Nature Biotechnology
- Published
- 2004-11
- Volume
- 22
- Issue
- 11
- Pages
- 1393-1398
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2118540273
- Cited by
- 2,032
- References
- 52
- Citations by year
- 2026: 52 · 2025: 51 · 2024: 66 · 2023: 66 · 2022: 64 · 2021: 77 · 2020: 89 · 2019: 114 · 2018: 162 · 2017: 118 · 2016: 95 · 2015: 135 · 2014: 108 · 2013: 145 · 2012: 111
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Transgenic Plants and Applications
- Keywords
- recombinant therapeutic proteins, mammalian cell culture, bioreactors, protein folding, post-translational modification, volumetric productivity, culture medium optimization, process control, vector engineering, host cell engineering
- MeSH terms
- Animals, Cells, Cultured, Humans, Mammals, Recombinant Proteins, Transfection, Protein Engineering, Cell Culture Techniques, Bioreactors, Genetic Enhancement
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.